Types of Delusions

Grandiose delusions are a type of delusion where the individual has an inflated sense of self-importance. They believe that they are related to a higher figure, such as a deity, a monarch, or a celebrity. They may also believe that they possess great wealth, power, or social status. These delusions are commonly seen in individuals with bipolar disorder during manic episodes, as well as in other psychotic disorders.

On the other hand, erotomanic delusions are a type of delusion where the individual believes that someone of a higher social status is in love with them. This type of delusion can be dangerous, as the individual may become obsessed with the object of their delusion and may engage in stalking or other inappropriate behaviors.

Nihilistic Delusions and Cotard Syndrome

Nihilistic delusions are a severe form of negative thinking often experienced by depressed patients. These delusions are characterized by an exaggerated belief that all or part of the patient’s body, mind, or the world has ceased to exist. Patients may report that they do not have a brain or bowel, or that their body has died and they are awaiting a burial. This type of thinking is associated with a lack of insight and can be dangerous, particularly if the patient refuses to eat or drink. Urgent treatment, such as electroconvulsive therapy (ECT), may be necessary.

Nihilistic delusions are not limited to depression and can also occur in psychotic disorders like schizophrenia and organic disorders like delirium. Cotard syndrome is a specific type of nihilistic delusion where the patient believes that they are dead. This syndrome is often associated with depression and can be a sign of severe mental illness.

Pseudohallucinations in Personality Disorders

Pseudohallucinations are hallucinations that patients recognize as not being real. These hallucinations can occur spontaneously and are different from true perception. Patients can stop them willingly. Patients with personality disorders, especially borderline personality disorder, may experience semi-psychotic and pseudohallucinatory episodes that are challenging to treat with medication. Psycho-social interventions and a strong therapeutic alliance are the primary therapeutic techniques, with medication as a secondary option.

Acute dystonia is characterized by sustained muscle contraction, such as torticollis or oculogyric crisis. These symptoms are unlikely to be caused by a brain tumor.

Neuroleptic malignant syndrome is often triggered by the initiation of anti-dopaminergic medication or withdrawal of dopamine agonists. Symptoms include fever, sweating, muscle rigidity, and confusion. Treatment involves discontinuing anti-dopaminergic medications and sometimes starting dopamine agonists like bromocriptine. Symptomatic care, such as cooling blankets, may also be provided. Antipyretics are not effective in treating neuroleptic malignant syndrome.

Oculogyric crisis is a dystonic reaction that typically occurs shortly after starting antipsychotics, particularly older typical antipsychotics. Treatment involves stopping the medication and administering antimuscarinic drugs.

A cranial nerve III palsy would result in a ‘down and out gaze,’ while a cranial nerve VI palsy would cause an inability to effectively abduct the eye.

Antipsychotics are a type of medication used to treat schizophrenia, psychosis, mania, and agitation. They are divided into two categories: typical and atypical antipsychotics. The latter were developed to address the extrapyramidal side-effects associated with the first generation of typical antipsychotics. Typical antipsychotics work by blocking dopaminergic transmission in the mesolimbic pathways through dopamine D2 receptor antagonism. However, they are known to cause extrapyramidal side-effects such as Parkinsonism, acute dystonia, akathisia, and tardive dyskinesia. These side-effects can be managed with procyclidine. Other side-effects of typical antipsychotics include antimuscarinic effects, sedation, weight gain, raised prolactin, impaired glucose tolerance, neuroleptic malignant syndrome, reduced seizure threshold, and prolonged QT interval. The Medicines and Healthcare products Regulatory Agency has issued specific warnings when antipsychotics are used in elderly patients due to an increased risk of stroke and venous thromboembolism.

Understanding Ego Defenses

Ego defenses are psychological mechanisms that individuals use to protect themselves from unpleasant emotions or thoughts. These defenses are classified into four levels, each with its own set of defense mechanisms. The first level, psychotic defenses, is considered pathological as it distorts reality to avoid dealing with it. The second level, immature defenses, includes projection, acting out, and projective identification. The third level, neurotic defenses, has short-term benefits but can lead to problems in the long run. These defenses include repression, rationalization, and regression. The fourth and most advanced level, mature defenses, includes altruism, sublimation, and humor.

Despite the usefulness of understanding ego defenses, their classification and definitions can be inconsistent and frustrating to learn for exams. It is important to note that these defenses are not necessarily good or bad, but rather a natural part of human behavior. By recognizing and understanding our own ego defenses, we can better manage our emotions and thoughts in a healthy way.

Psychomotor Retardation in Severe Depression

Psychomotor retardation is a cognitive symptom commonly observed in individuals with severe depression. It is characterized by a significant slowing down of both thinking and behavior. This symptom can manifest in various ways, such as slowed speech, reduced movement, and delayed responses.

In contrast, other disorders such as mania and schizophrenia are associated with different forms of thought disorders. Mania is characterized by racing thoughts and impulsivity, while schizophrenia is associated with disorganized thinking and delusions.

It is important to recognize the presence of psychomotor retardation in individuals with severe depression as it can significantly impact their daily functioning and quality of life. Treatment options for this symptom may include medication, psychotherapy, and lifestyle changes. By addressing this symptom, individuals with severe depression can improve their overall well-being and ability to function in their daily lives.

Typical antipsychotics are more likely to cause extrapyramidal side-effects (EPSEs) than atypical antipsychotics. Haloperidol is the only typical antipsychotic among the given options, while aripiprazole, olanzapine, quetiapine, and risperidone are all atypical antipsychotics. EPSEs include Parkinsonism, akathisia, acute dystonia, and tardive dyskinesia. Atypical antipsychotics have a lower risk of causing EPSEs than older antipsychotics, but they may still cause them at higher doses. However, atypical antipsychotics carry a higher risk of metabolic side effects such as weight gain, diabetes mellitus, and hyperlipidaemia. Examples of typical antipsychotics licensed for use in the UK include haloperidol, trifluperazine, chlorpromazine, pericyazine, levomepromazine, and flupentixol. Examples of atypical antipsychotics licensed for use in the UK include amisulpride, aripiprazole, clozapine, lurasidone, olanzapine, paliperidone, and quetiapine.

Antipsychotics are a type of medication used to treat schizophrenia, psychosis, mania, and agitation. They are divided into two categories: typical and atypical antipsychotics. The latter were developed to address the extrapyramidal side-effects associated with the first generation of typical antipsychotics. Typical antipsychotics work by blocking dopaminergic transmission in the mesolimbic pathways through dopamine D2 receptor antagonism. However, they are known to cause extrapyramidal side-effects such as Parkinsonism, acute dystonia, akathisia, and tardive dyskinesia. These side-effects can be managed with procyclidine. Other side-effects of typical antipsychotics include antimuscarinic effects, sedation, weight gain, raised prolactin, impaired glucose tolerance, neuroleptic malignant syndrome, reduced seizure threshold, and prolonged QT interval. The Medicines and Healthcare products Regulatory Agency has issued specific warnings when antipsychotics are used in elderly patients due to an increased risk of stroke and venous thromboembolism.

Anxiety is a common disorder that can manifest in various ways. According to NICE, the primary feature is excessive worry about multiple events associated with heightened tension. It is crucial to consider potential physical causes when diagnosing psychiatric disorders such as anxiety. Hyperthyroidism, cardiac disease, and medication-induced anxiety are important alternative causes. Medications that may trigger anxiety include salbutamol, theophylline, corticosteroids, antidepressants, and caffeine.

NICE recommends a step-wise approach for managing generalised anxiety disorder (GAD). The first step is education about GAD and active monitoring. The second step involves low-intensity psychological interventions such as individual non-facilitated self-help, individual guided self-help, or psychoeducational groups. The third step includes high-intensity psychological interventions such as cognitive behavioural therapy or applied relaxation, or drug treatment. Sertraline is the first-line SSRI recommended by NICE. If sertraline is ineffective, an alternative SSRI or a serotonin–noradrenaline reuptake inhibitor (SNRI) such as duloxetine or venlafaxine may be offered. If the person cannot tolerate SSRIs or SNRIs, pregabalin may be considered. For patients under the age of 30 years, NICE recommends warning them of the increased risk of suicidal thinking and self-harm and weekly follow-up for the first month.

The management of panic disorder also follows a stepwise approach. The first step is recognition and diagnosis, followed by treatment in primary care. NICE recommends either cognitive behavioural therapy or drug treatment. SSRIs are the first-line treatment. If contraindicated or no response after 12 weeks, imipramine or clomipramine should be offered. The third step involves reviewing and considering alternative treatments, followed by review and referral to specialist mental health services in the fourth and fifth steps, respectively.

Psychomotor Retardation in Depression

Psychomotor retardation is a common manifestation of depression, characterized by slow movement, speech, and rigidity in limbs. Patients may also exhibit a bent body posture and feelings of emptiness and hopelessness. It is crucial to rule out other potential causes, such as medication side effects or neurological disorders like Parkinson’s disease.

In severe cases, psychomotor retardation can progress to catatonia, where the patient is unresponsive to external stimuli despite being awake. It is essential to recognize and address these symptoms promptly to ensure proper diagnosis and treatment. By the signs and symptoms of psychomotor retardation, healthcare professionals can provide appropriate care and support to individuals experiencing depression.

Benzodiazepines are a class of drugs that act as central nervous system depressants by enhancing the effects of the neurotransmitter gamma-aminobutyric acid (GABA). They are commonly used to treat anxiety, insomnia, and seizures.

In March 2018, NICE released new guidelines for the recognition and management of Attention Deficit Hyperactivity Disorder (ADHD). This condition can have a significant impact on a child’s life and can continue into adulthood, making accurate diagnosis and treatment crucial. ADHD is defined by DSM-V as a persistent condition that includes features of inattention and/or hyperactivity/impulsivity, with an element of developmental delay. The threshold for diagnosis is six features for children up to 16 years old and five features for those aged 17 or over. ADHD has a prevalence of 2.4% in the UK, with a possible genetic component and a higher incidence in boys than girls.

NICE recommends a holistic approach to treating ADHD that is not solely reliant on medication. After presentation, a ten-week observation period should follow to determine if symptoms change or resolve. If symptoms persist, referral to secondary care is necessary, usually to a paediatrician with a special interest in behavioural disorders or to the local Child and Adolescent Mental Health Service (CAMHS). A tailored plan of action should be developed, taking into account the patient’s needs and wants and how their condition affects their lives.

Drug therapy should be considered a last resort and is only available to those aged 5 years or older. For patients with mild/moderate symptoms, parents attending education and training programmes can be beneficial. For those who fail to respond or have severe symptoms, pharmacotherapy can be considered. Methylphenidate is the first-line treatment for children and should be given on a six-week trial basis. Lisdexamfetamine can be used if there is an inadequate response, and dexamfetamine can be started in those who have benefited from lisdexamfetamine but cannot tolerate its side effects. In adults, methylphenidate or lisdexamfetamine are first-line options, with switching between drugs if no benefit is seen after a trial of the other.

All of these drugs have the potential to be cardiotoxic, so a baseline ECG should be performed before starting treatment. Referral to a cardiologist is necessary if there is any significant past medical history or family history, or any doubt or ambiguity. A thorough history and clinical examination are essential for accurate diagnosis, given the overlap of ADHD with many other psychiatric and physical conditions.